菜单

Press Releases

WuXi Biologics Included in MSCI Selection Indexes for Third Consecutive Year
June 20, 2025
WuXi Biologics Included in MSCI Selection Indexes for Third Consecutive Year
  • Recognized by MSCI with AAA ESG Rating
  • Leader in Green CRDMO solutions for a healthier future
  • Empowering global clients to fulfill their sustainability commitments

 

Shanghai, June 20, 2025 – WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been included in 2025 MSCI Selection Indexes for the third consecutive year, underscoring continued recognition from global capital markets of the company’s sustainability commitment, as well as its leadership in the biopharmaceutical industry.

 

 

The MSCI Selection Indexes are designed to reflect the performance of companies with high ESG ratings relative to their sector peers. They are built for institutional investors seeking exposure to companies with a strong sustainability profile and a relatively low tracking error in relation to the underlying equity market. According to MSCI, the number of ETFs and ETF assets linked to MSCI Sustainability and Climate Change indexes ranks the top globally among others. WuXi Biologics — with outstanding performance in areas of Product Safety and Quality, Human Capital Development, Corporate Governance and Corporate Behavior, and Climate Change —has been granted MSCI’s highest AAA rating each year since 2023.

 

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, “We are very pleased to once again be selected for the MSCI Selection Indexes, a testament of our continued dedication to enhancing our sustainability performance. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable clients worldwide to fulfill their ESG commitments, and work with all stakeholders to promote responsible practices throughout the entire value chain.”

 

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively contributes to advocating sustainability and has earned widespread recognitions for its efforts. The company was awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security “A list” and awarded an A- CDP Climate Change leadership-level score for two consecutive years; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).

 

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

 

Contacts

 

ESG

esg@wuxibiologics.com

 

Media

PR@wuxibiologics.com

 

MSCI Disclaimer

The inclusion of WuXi Biologics in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of WuXi Biologics by MSCI or any of its affiliates. The MSCI indexes are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service marks of MSCI or its affiliates.